News and Trends 3 May 2023
Eterna acquires allogeneic immuno-oncology platform from Exacis
Eterna Therapeutics Inc. has announced the acquisition of the global immuno-oncology platform of Exacis Biotherapeutics. The acquisition complements Eterna Therapeutics’…